Amylyx’s patient education…
Amylyx’s patient education website aims to empower patients to navigate [...]
A Daiichi Sankyo quarterly report…
A Daiichi Sankyo quarterly report that should have celebrated strong [...]
Seven years after it was approved,…
Seven years after it was approved, AbbVie’s Skyrizi has proven [...]
A phase 3 trial of Novo…
A phase 3 trial of Novo Nordisk’s ziltivekimab has missed [...]
Apnimed has raised $192 million…
Apnimed has raised $192 million for its upsized IPO, with [...]
Shionogi’s “Got the Call, Make…
Shionogi’s “Got the Call, Make the Call” campaign for COVID [...]
Following a pair of FDA rejections…
Following a pair of FDA rejections of its melanoma drug, [...]
Legend Biotech CEO Ying Huang,…
Legend Biotech CEO Ying Huang, Ph.D., has left the company [...]
Legend Biotech’s Ying Huang,…
Legend Biotech’s Ying Huang, Ph.D., resigned after a six-year stint [...]
In hopes of challenging Incyte’s…
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer [...]